Muscular Dystrophy Compound with HMB Moiety for Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for muscular dystrophy, such as ataluren, have proven inefficacy and require reconstitution of clinical trials, necessitating a more effective compound for treatment and prevention of the disease.
Innovation Solution
A novel compound with a specific structure, represented by Chemical Formula 1, is introduced, which improves bioavailability, absorption rate, and physicochemical properties by incorporating a functional group that separates into beta-hydroxy beta-methyl butyric acid (HMB), combining the pharmacological effects of ataluren and HMB to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ataluren is used as a treatment for muscular dystrophy, then it can act on ribosome to improve protein synthesis, but its efficacy has not been substantially proven and requires reconstitution of clinical trials
Solution Approach 1:
The patent modifies the chemical structure of ataluren by introducing a specific functional group (beta-hydroxy beta-methyl butyric acid moiety) to create a derivative compound. This structural parameter change aims to improve the compound's efficacy and bioavailability while maintaining its mechanism of action on ribosomes, thereby addressing the unproven efficacy issue without requiring complete reconstitution of clinical trials.
Solution Approach 2:
The invention creates a composite molecular structure by combining ataluren with beta-hydroxy beta-methyl butyric acid (HMB) functionality. This composite approach integrates the ribosome-targeting capability of ataluren with the muscle-protective properties of HMB, potentially enhancing overall therapeutic efficacy and providing dual mechanisms of action for treating muscular dystrophy.
2Reliability
If ataluren is administered, then it can proceed through protein synthesis, but its bioavailability and absorption rate are insufficient
Solution Approach 1:
The patent alters the physicochemical parameters of ataluren by adding a functional group that improves bioavailability and absorption rate. The beta-hydroxy beta-methyl butyric acid moiety is specifically chosen to enhance the compound's pharmacokinetic properties, including its ability to be absorbed and utilized by the body, thereby improving therapeutic effect without requiring increased dosing.
3Reliability
If a new compound structure is introduced to improve efficacy, then bioavailability and absorption rate improve, but the molecular structure becomes more complex
Solution Approach 1:
The patent introduces a specific functional group with defined chemical parameters (beta-hydroxy beta-methyl butyric acid) rather than making arbitrary structural modifications. This targeted parameter change improves efficacy and bioavailability while minimizing unnecessary molecular complexity. The added moiety has a specific structure that serves multiple functions including improving absorption and providing muscle-protective effects.
Data Source
AI summary
The present invention relates to a novel compound and a medicinal use of the novel compound. In particular, the present invention relates to a novel compound useful for the treatment and/or prevention of muscular dystrophy, including Duchenne muscular atrophy, and a medicinal use of the novel compound.